| Literature DB >> 24383821 |
Avi Elbaz, Amit Mor1, Ganit Segal, Yoav Aloni, Yee Hong Teo, Yee Sze Teo, Shamal Das-De, Seng Jin Yeo.
Abstract
BACKGROUND: Previous studies have shown the effect of a unique therapy with a non-invasive biomechanical foot-worn device (AposTherapy) on Caucasian western population suffering from knee osteoarthritis. The purpose of the current study was to evaluate the effect of this therapy on the level of symptoms and gait patterns in a multi-ethnic Singaporean population suffering from knee osteoarthritis.Entities:
Mesh:
Year: 2014 PMID: 24383821 PMCID: PMC3892089 DOI: 10.1186/1749-799X-9-1
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Figure 1Flow chart of assessment, enrolment and follow-up.
Figure 2Apos System. () Biomechanical device comprising two individually calibrated elements and a foot-worn platform. The elements are attached to a platform under the hindfoot and forefoot regions. () The biomechanical elements are available in different degrees of convexity and resilience. () The specially designed sole of the platform includes two mounting rails and a positioning matrix to enable flexible positioning of each biomechanical element.
Changes in spatio-temporal gait parameters following 6 months of therapy
| Velocity (cm/s) | 86.9 (16.4) | 98.8 (16.1) | 100.7 (16.5) | <0.001 |
| [82.4–91.3] | [94.4–103.2] | [96.2–105.2] | ||
| Step length MS (cm) | 49.4 (7.9) | 53.7 (7.3) | 54.5 (7.5) | <0.001 |
| [47.3–51.6] | [51.7–55.7] | [52.5–56.6] | ||
| Step length LS (cm) | 50.0 (7.5) | 54.0 (7.2) | 54.7 (7.8) | <0.001 |
| [48.0–52.1] | [52.0–56.0] | [52.6–56.8] | ||
| Stance MS (% GC) | 71.4 (7.3) | 67.3 (6.9) | 67.2 (7.4) | <0.001 |
| [69.4–73.3] | [65.4–69.2] | [65.2–69.2] | ||
| Stance LS (% GC) | 72.8 (7.4) | 67.2 (8.1) | 67.4 (6.5) | <0.001 |
| [70.7–74.8] | [65.0–69.5] | [65.6–69.2] | ||
| Single-limb support MS (% GC) | 37.2 (2.6) | 37.2 (2.5) | 38.1 (2.5) | 0.001 |
| [36.5–37.9] | [37.5–38.8] | [37.4–38.8] | ||
| Single-limb support LS (% GC) | 38.7 (2.3) | 39.0 (1.9) | 39.2 (1.9) | 0.027 |
| [38.1–39.4] | [38.5–39.5] | [38.7–39.7] |
Results are presented as mean (SD) [95% CI]. MS more symptomatic, LS less symptomatic, GC gait cycle. Set P < 0.05.
Figure 3Changes in WOMAC pain, stiffness and function following 6 months of therapy. The WOMAC questionnaire includes 24 questions in a VAS format (0 = no pain/stiffness/difficulty, 10 = severe pain/stiffness/difficulty).
Changes in SF-36 quality of life following 6 months of therapy
| Physical function | 45.2 (20.1) | 56.9 (19.7) | 61.9 (21.5) | <0.001 |
| [39.7–50.7] | [51.6–62.3] | [56.0–67.7] | ||
| Limitation due to physical health | 29.8 (34.0) | 55.3 (42.4) | 75.0 (33.6) | <0.001 |
| [20.4–39.3] | [43.5–67.1] | [65.7–84.3] | ||
| Limitations due to emotional problems | 59.8 (44.5) | 71.8 (39.8) | 84.6 (28.4) | <0.001 |
| [47.4–72.2] | [60.7–82.9] | [76.7–92.5] | ||
| Vitality | 52.5 (17.2) | 58.9 (17.0) | 60.3 (17.8) | 0.004 |
| [47.8–57.2] | [54.2–63.5] | [55.4–65.1] | ||
| Emotional well being | 68.0 (10.9) | 69.9 (11.7) | 71.0 (9.5) | 0.061 |
| [65.1–71.0] | [66.7–73.0] | [68.5–73.6] | ||
| Social functioning | 65.6 (22.9) | 73.8 (21.9) | 75.7 (19.9) | 0.004 |
| [59.3–71.8] | [67.9–79.8] | [70.3–81.2] | ||
| Pain | 48.3 (20.0) | 63.4 (20.7) | 62.3 (21.3) | 0.001 |
| [42.8–53.8] | [57.7–69.0] | [56.4–68.1] | ||
| General health | 50.5 (19.1) | 60.1 (19.1) | 66.3 (17.1) | <0.001 |
| [44.3–55.7] | [54.9–65.3] | [61.6–70.9] | ||
| Physical Score | 44.7 (14.5) | 59.0 (18.0) | 65.3 (17.7) | <0.001 |
| [40.8–48.7] | [54.1–64.0] | [60.5–70.1] | ||
| Mental Score | 58.5 (16.0) | 67.0 (16.3) | 71.7 (13.4) | <0.001 |
| [54.2–62.9] | [62.5–71.4] | [68.0–75.3] |
SF-36 Health Survey includes 36 questions. Results range between 0 and 100 (0 = poor quality of life, 100 = high quality of life). Set P < 0.05.